Alzamend Neuro Inc. (ALZN) announced Wednesday that it has wrapped up the clinical portion of its first Phase 2 study of AL001 in healthy human participants. Topline data should arrive in the first quarter of 2026.

That's a slight delay from the original timeline, which had results coming by year-end 2025. The company still plans to launch follow-up trials targeting bipolar disorder, major depressive disorder, post-traumatic stress disorder, and Alzheimer's disease through early 2026.

Rethinking Lithium Delivery

Working with Massachusetts General Hospital as the clinical trial site, Alzamend is investigating what makes AL001 different from conventional lithium treatments. AL001, also known as LiProSal, is a novel, patented oral drug candidate designed as a safer and more effective lithium-delivery system compared to traditional lithium salts.

The core question: Can AL001 deliver lithium to the brain more efficiently than marketed lithium salts while reducing the systemic side effects that have limited lithium's broader adoption?

Lithium has long been recognized as one of the most effective first-line treatments for managing manic episodes and maintenance therapy in bipolar disorder. The problem is that therapeutic drug monitoring challenges have held it back. Traditional lithium salts approved by the U.S. Food and Drug Administration operate within a narrow therapeutic index, requiring frequent clinician-monitored plasma lithium and blood chemistry tests to prevent adverse effects.

That's where AL001 could change the game. By potentially removing the requirement for lithium therapeutic drug monitoring, AL001 might transform treatment for at-risk patient populations and improve clinical outcomes across multiple conditions.

Advanced Imaging Technology

The clinical study utilized an engineered head coil developed by Tesla Dynamic Coils BV, which enables high-resolution, whole-brain lithium imaging. This technology allows researchers to precisely quantify lithium concentrations within specific brain structures, creating proprietary imaging data sets that will help Alzamend identify optimal, disease-specific target doses of AL001.

Through reduced systemic exposure, Alzamend's AL001 formulation may represent a paradigm shift in treating disorders like Alzheimer's by lowering the risks of kidney and thyroid complications commonly associated with conventional lithium regimens.

The Broader Pipeline

Alzamend isn't putting all its eggs in one basket. The company's secondary therapeutic drug candidate, ALZN002, takes a completely different approach. It's a proprietary active immunotherapy product, meaning it's produced by the patient's own immune system.

ALZN002 uses autologous dendritic cells engineered to target amyloid-beta proteins, aiming for safe, long-lasting reduction of beta-amyloid plaques. This differs from antibody-based approaches that rely on foreign products introduced into the body.

In April 2023, Alzamend Neuro (ALZN) initiated a Phase 1/2A trial for ALZN002 to evaluate its safety, tolerability, and efficacy in 20-30 patients with mild to moderate Alzheimer's disease, comparing multiple ascending doses to a placebo.

ALZN Price Action: Alzamend Neuro shares were up 7.79% at $2.63 during premarket trading on Tuesday.